The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib. Read ...

The investigational combination of bezuclastinib (CGT9486) and sunitinib (Sutent) yielded clinically meaningful benefits with favorable tolerability in patients with gastrointestinal stromal tumors ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

The modern kitchen contains numerous ingredients that individually provide nutrition and flavor, yet certain combinations create unexpected chemical reactions that can poison the body. These dangerous ...

Members of a key vaccine panel have delayed a pivotal vote regarding the hepatitis B vaccine, while voting to amend recommendations to combination shots that target measles, mumps, rubella and ...